These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 26591395)

  • 21. [The efficacy of switch therapy in community-acquired pneumonia in Japan].
    Uchiyama N; Aoshima M; Satoh T; Chonabayashi N
    Nihon Kokyuki Gakkai Zasshi; 2003 Apr; 41(4):261-7. PubMed ID: 12795180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of exclusively oral antibiotic therapy in patients hospitalized with nonsevere community-acquired pneumonia: a retrospective study and meta-analysis.
    Marras TK; Nopmaneejumruslers C; Chan CK
    Am J Med; 2004 Mar; 116(6):385-93. PubMed ID: 15006587
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early switch and early discharge strategies in patients with community-acquired pneumonia: a meta-analysis.
    Rhew DC; Tu GS; Ofman J; Henning JM; Richards MS; Weingarten SR
    Arch Intern Med; 2001 Mar; 161(5):722-7. PubMed ID: 11231705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative efficacy of amoxicillin, cefuroxime and clarithromycin in the treatment of community -acquired pneumonia in children.
    Aurangzeb B; Hameed A
    J Coll Physicians Surg Pak; 2003 Dec; 13(12):704-7. PubMed ID: 15569557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial.
    Oosterheert JJ; Bonten MJ; Schneider MM; Buskens E; Lammers JW; Hustinx WM; Kramer MH; Prins JM; Slee PH; Kaasjager K; Hoepelman AI
    BMJ; 2006 Dec; 333(7580):1193. PubMed ID: 17090560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of oral amoxicillin and intravenous benzyl penicillin for community acquired pneumonia in children (PIVOT trial): a multicentre pragmatic randomised controlled equivalence trial.
    Atkinson M; Lakhanpaul M; Smyth A; Vyas H; Weston V; Sithole J; Owen V; Halliday K; Sammons H; Crane J; Guntupalli N; Walton L; Ninan T; Morjaria A; Stephenson T
    Thorax; 2007 Dec; 62(12):1102-6. PubMed ID: 17567657
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Full-course oral levofloxacin for treatment of hospitalized patients with community-acquired pneumonia.
    Erard V; Lamy O; Bochud PY; Bille J; Cometta A; Calandra T
    Eur J Clin Microbiol Infect Dis; 2004 Feb; 23(2):82-8. PubMed ID: 14727149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.
    File TM; Rewerska B; Vucinic-Mihailovic V; Gonong JRV; Das AF; Keedy K; Taylor D; Sheets A; Fernandes P; Oldach D; Jamieson BD
    Clin Infect Dis; 2016 Oct; 63(8):1007-1016. PubMed ID: 27448679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Getting physicians to make "the switch": the role of clinical guidelines in the management of community-acquired pneumonia.
    Hagaman JT; Yurkowski P; Trott A; Rouan GW
    Am J Med Qual; 2005; 20(1):15-21. PubMed ID: 15782751
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and bacteriological outcomes in hospitalised patients with community-acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone plus clarithromycin or erythromycin: a prospective, randomised, multicentre study.
    Tamm M; Todisco T; Feldman C; Garbino J; Blasi F; Hogan P; de Caprariis PJ; Hoepelman IM
    Clin Microbiol Infect; 2007 Feb; 13(2):162-171. PubMed ID: 17328728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycin.
    Niederman MS; Chang JR; Stewart J; Nusrat R; Nieman RB
    Curr Med Res Opin; 2004 May; 20(5):749-56. PubMed ID: 15140342
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Duration and route of antibiotic therapy in community-acquired pneumonia: switch and step-down therapy.
    Cassiere HA; Fein AM
    Semin Respir Infect; 1998 Mar; 13(1):36-42. PubMed ID: 9543474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial.
    Carratalà J; Garcia-Vidal C; Ortega L; Fernández-Sabé N; Clemente M; Albero G; López M; Castellsagué X; Dorca J; Verdaguer R; Martínez-Montauti J; Manresa F; Gudiol F
    Arch Intern Med; 2012 Jun; 172(12):922-8. PubMed ID: 22732747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacoeconomic considerations associated with the use of intravenous-to-oral moxifloxacin for community-acquired pneumonia.
    Davis SL; Delgado G; McKinnon PS
    Clin Infect Dis; 2005 Jul; 41 Suppl 2():S136-43. PubMed ID: 15942880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic review on antibiotic therapy for pneumonia in children between 2 and 59 months of age.
    Lassi ZS; Das JK; Haider SW; Salam RA; Qazi SA; Bhutta ZA
    Arch Dis Child; 2014 Jul; 99(7):687-93. PubMed ID: 24431417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence-based emergency medicine/critically appraised topic. Evidence behind the 4-hour rule for initiation of antibiotic therapy in community-acquired pneumonia.
    Yu KT; Wyer PC
    Ann Emerg Med; 2008 May; 51(5):651-62, 662.e1-2. PubMed ID: 18272253
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can an antimicrobial stewardship program reduce length of stay of immune-competent adult patients admitted to hospital with diagnosis of community-acquired pneumonia? Study protocol for pragmatic controlled non-randomized clinical study.
    DiDiodato G; McArthur L; Beyene J; Smieja M; Thabane L
    Trials; 2015 Aug; 16():355. PubMed ID: 26272324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical efficacy and safety of moxifloxacin versus levofloxacin plus metronidazole for community-acquired pneumonia with aspiration factors.
    Sun T; Sun L; Wang R; Ren X; Sui DJ; Pu C; Ren Y; Liu Y; Yang Z; Li F
    Chin Med J (Engl); 2014; 127(7):1201-5. PubMed ID: 24709166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Diagnostic value of serum procalcitonin in identifying the etiology of non-responding community-acquired pneumonia after initial antibiotic therapy].
    Wang Z; Zhang X; Wu J; Zhang W; Kuang H; Li X; Xuan W; Wang K; Ma L
    Zhonghua Jie He He Hu Xi Za Zhi; 2014 Nov; 37(11):824-30. PubMed ID: 25604112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early switch therapy from intravenous sulbactam/ampicillin to oral garenoxacin in patients with community-acquired pneumonia: a multicenter, randomized study in Japan.
    Kohno S; Yanagihara K; Yamamoto Y; Tokimatsu I; Hiramatsu K; Higa F; Tateyama M; Fujita J; Kadota J
    J Infect Chemother; 2013 Dec; 19(6):1035-41. PubMed ID: 23695232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.